Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 9(5): e96370, 2014.
Article in English | MEDLINE | ID: mdl-24823794

ABSTRACT

Acetyl Coenzyme A-dependent N-, O- and N,O-acetylation of aromatic amines and hydrazines by arylamine N-acetyltransferases is well characterised. Here, we describe experiments demonstrating that human arylamine N-acetyltransferase Type 1 and its murine homologue (Type 2) can also catalyse the direct hydrolysis of acetyl Coenzyme A in the presence of folate. This folate-dependent activity is exclusive to these two isoforms; no acetyl Coenzyme A hydrolysis was found when murine arylamine N-acetyltransferase Type 1 or recombinant bacterial arylamine N-acetyltransferases were incubated with folate. Proton nuclear magnetic resonance spectroscopy allowed chemical modifications occurring during the catalytic reaction to be analysed in real time, revealing that the disappearance of acetyl CH3 from acetyl Coenzyme A occurred concomitantly with the appearance of a CH3 peak corresponding to that of free acetate and suggesting that folate is not acetylated during the reaction. We propose that folate is a cofactor for this reaction and suggest it as an endogenous function of this widespread enzyme. Furthermore, in silico docking of folate within the active site of human arylamine N-acetyltransferase Type 1 suggests that folate may bind at the enzyme's active site, and facilitate acetyl Coenzyme A hydrolysis. The evidence presented in this paper adds to our growing understanding of the endogenous roles of human arylamine N-acetyltransferase Type 1 and its mouse homologue and expands the catalytic repertoire of these enzymes, demonstrating that they are by no means just xenobiotic metabolising enzymes but probably also play an important role in cellular metabolism. These data, together with the characterisation of a naphthoquinone inhibitor of folate-dependent acetyl Coenzyme A hydrolysis by human arylamine N-acetyltransferase Type 1/murine arylamine N-acetyltransferase Type 2, open up a range of future avenues of exploration, both for elucidating the developmental role of these enzymes and for improving chemotherapeutic approaches to pathological conditions including estrogen receptor-positive breast cancer.


Subject(s)
Acetyl-CoA Hydrolase/metabolism , Acetyltransferases/metabolism , Arylamine N-Acetyltransferase/metabolism , Folic Acid/metabolism , Isoenzymes/metabolism , Acetylation , Animals , Humans , Hydrolysis , Mice , Nuclear Magnetic Resonance, Biomolecular
2.
Bioorg Med Chem ; 22(11): 3030-54, 2014 Jun 01.
Article in English | MEDLINE | ID: mdl-24758871

ABSTRACT

A naphthoquinone inhibitor of human arylamine N-acetyltransferase 1 (hNAT1), a potential cancer biomarker and therapeutic target, has been reported which undergoes a distinctive concomitant color change from red to blue upon binding to the enzyme. Here we describe the use of in silico modeling alongside structure-activity relationship studies to advance the hit compound towards a potential probe to quantify hNAT1 levels in tissues. Derivatives with both a fifty-fold higher potency against hNAT1 and a two-fold greater absorption coefficient compared to the initial hit have been synthesized; these compounds retain specificity for hNAT1 and its murine homologue mNat2 over the isoenzyme hNAT2. A relationship between pKa, inhibitor potency and colorimetric properties has also been uncovered. The high potency of representative examples against hNAT1 in ZR-75-1 cell extracts also paves the way for the development of inhibitors with improved intrinsic sensitivity which could enable detection of hNAT1 in tissue samples and potentially act as tools for elucidating the unknown role hNAT1 plays in ER+ breast cancer; this could in turn lead to a therapeutic use for such inhibitors.


Subject(s)
Arylamine N-Acetyltransferase/antagonists & inhibitors , Biomarkers, Tumor/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Isoenzymes/antagonists & inhibitors , Naphthoquinones/pharmacology , Arylamine N-Acetyltransferase/metabolism , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Colorimetry , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Humans , Isoenzymes/metabolism , Models, Molecular , Molecular Structure , Naphthoquinones/chemical synthesis , Naphthoquinones/chemistry , Structure-Activity Relationship
3.
PLoS One ; 8(8): e70600, 2013.
Article in English | MEDLINE | ID: mdl-23940600

ABSTRACT

Human arylamine N-acetyltransferase 1 (hNAT1) has become an attractive potential biomarker for estrogen-receptor-positive breast cancers. We describe here the mechanism of action of a selective non-covalent colorimetric biosensor for the recognition of hNAT1 and its murine homologue, mNat2, over their respective isoenzymes, leading to new opportunities in diagnosis. On interaction with the enzyme, the naphthoquinone probe undergoes an instantaneous and striking visible color change from red to blue. Spectroscopic, chemical, molecular modelling and biochemical studies reported here show that the color change is mediated by selective recognition between the conjugate base of the sulfonamide group within the probe and the conjugate acid of the arginine residue within the active site of both hNAT1 and mNat2. This represents a new mechanism for selective biomarker sensing and may be exploited as a general approach to the specific detection of biomarkers in disease.


Subject(s)
Arylamine N-Acetyltransferase/chemistry , Arylamine N-Acetyltransferase/metabolism , Biomarkers, Tumor/chemistry , Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Color , Isoenzymes/chemistry , Isoenzymes/metabolism , Naphthoquinones/chemistry , Naphthoquinones/metabolism , Animals , Catalytic Domain , Female , Humans , Mice , Protein Binding
SELECTION OF CITATIONS
SEARCH DETAIL
...